ArticlePLOS mental health2026
Association between the combination of GABAergic agents and SSRIs at the first clinical visit and depressive symptom trajectories: A study using group-based trajectory modeling and Apriori algorithm.
Article in PLOS mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a leading cause of disability, with limited efficacy of current treatments: 30% - 40% of major depressive disorder patients fail first-line therapy, and relapse rates remain high. Combination pharmacotherapy shows promise, but real-world evidence on initial treatment strategies and longitudinal symptom trajectories is lacking. We conducted a longitudinal analysis of electronic health records from 1,876 patients who visited the Shanghai Mental Health Center between November 2021 and April 2023. Group-based trajectory modeling (GBTM) classified patients into subgroups based on PHQ-9 score trajectories. The Apriori algorithm identified common medication mechanism combinations for the first visit. Multinomial logistic regression evaluated associations between medication groups and trajectory subgroups. General linear modeling examined SDS score improvement. Network pharmacology was conducted as an exploratory analysis to investigate potential biological context. Three PHQ-9 trajectory groups were identified: Rapid Decline (29.96%), Gradual Decline (30.76%), and Worsening (39.28%). The Worsening Group had lower initial PHQ-9 scores but showed progressive severity elevation. Four medication mechanism combination groups were identified including GABAergic agents alone (GABA), selective serotonin reuptake inhibitors alone (SSRIs), GABA+SSRIs combination, and Others. GABA+SSRIs was the most frequent combination (31.02%). Compared with GABA+SSRIs, patients in the SSRIs group (OR adj, 1.809; 95% CI, 1.196 - 2.736) had significantly higher odds of belonging to the Worsening Group (P = 0.005). In the supplementary SDS analysis, GABA monotherapy was associated with significantly less symptom improvement than GABA+SSRIs (β = -1.790, 95% CI: -3.320, -0.258). Network analysis identified 33 intersecting targets between GABA+SSRIs and depression, enriched in neurotransmission and synaptic plasticity pathways. Overall, the combination of GABAergic agents and SSRIs at the first clinical visit was associated with a more favorable PHQ-9 trajectory group than SSRIs monotherapy. These findings may inform future prospective and mechanistic studies on medication mechanism combinations in depression treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.